Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other financing activities (2024 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Other financing activities for 2 consecutive years, with $1.6 million as the latest value for Q1 2025.

  • Quarterly Other financing activities rose 207.96% to $1.6 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 207.96% year-over-year, with the annual reading at $1.6 million for FY2025, 207.96% up from the prior year.
  • Other financing activities hit $1.6 million in Q1 2025 for NewAmsterdam Pharma, up from $515000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.6 million in Q1 2025 to a low of $515000.0 in Q1 2024.